Geneva, Switzerland and Boston, MA - 31 May 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder, Tim ADAMS, CFO, and Mario CORSO, Senior Director Investor Relations will attend the Jefferies Healthcare Conference. Management will be presenting on Thursday June 8th at 08:30 a.m. and will be hosting one-on-one meetings at the Grand Hyatt Hotel in New York City.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Company Contact:
CEO Office contact
Delphine Renaud
[email protected]
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/70181aa5-664e-4bd9-a30f-7dcaa32de878


Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 



